Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution.

Abstract

Metaiodobenzylguanidine (MIBG) is an enzymatically stable synthetic analog of norepinephrine that when radiolabled with diagnostic ((123)I) or therapeutic ((131)I) isotopes has been shown to concentrate highly in sympathetically innervated tissues such as the heart and neuroendocrine tumors that possesses high levels of norepinephrine transporter (NET). As… (More)
DOI: 10.1089/cbr.2009.0695

Topics

Cite this paper

@article{Barrett2010ComparisonOH, title={Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution.}, author={John A. Barrett and John L. Joyal and Shawn M. Hillier and Kevin P. Maresca and Frank J Femia and James F. Kronauge and Marie T. Boyd and Robert J. Mairs and John Babich}, journal={Cancer biotherapy & radiopharmaceuticals}, year={2010}, volume={25 3}, pages={299-308} }